Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD (INHALE)

Novartis

Status: Completed

Conditions: Chronic Obstructive Pulmonary Disease

Treatments: Drug: Indacaterol (Onbrez®) /QAB149

Study type: Observational

Funder types: Industry

Identifiers

NCT02123199

CQAB149BGB01

Details and patient eligibility

About

A prospective observational multi centre research study in GP practices clustered within up to 10 UK Primary care trusts.

Enrollment: 103 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with active diagnosis of COPD, confirmed by spirometry documented in medical notes

Exclusion criteria

• Patients who are currently receiving other maintenance therapy (except LAMA) for COPD.
• Patients previously prescribed Indacaterol.

Trial design

103 participants in 1 patient group

Indacaterol/QAB149

Description:

Patients treated with Indacaterol for COPD prior to enrollment in study

Treatment:

Drug: Indacaterol (Onbrez®) /QAB149